Celcuity (CELC)

• Market cap: $459M
• 1 day: -3.58%
• 5 days: -7.35%
• 1 month: 11.92%
• 3 months: 20.74%
• 6 months: -3.27%
• Year to date: -7.77%
• 1 year: -21.06%
• 5 years: 39.68%
• 10 years: -15.26%
• Sector: Healthcare
• Industry: Biotechnology

About: Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Employees: 87

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

26% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 27

1.39% more ownership

Funds ownership: 81.83% [Q4 2024] → 83.22% (+1.39%) [Q1 2025]

9% less funds holding

Funds holding: 103 [Q4 2024] → 94 (-9) [Q1 2025]

22% less capital invested

Capital invested by funds: $402M [Q4 2024] → $312M (-$89.4M) [Q1 2025]

36% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 22

50% less funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]

63% less call options, than puts

Call options by funds: $192K | Put options by funds: $525K

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $27 123% upside
• Avg. target: $28 131% upside
• High target: $29 139% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Swayampakula Ramakanth	123% upside $27	Buy Reiterated	19 May 2025
Needham Gil Blum	139% upside $29	Buy Reiterated	15 May 2025